Infographic

Infographic: Oncogenic Drivers of Pediatric Low-Grade Glioma (pLGG)

05/13/2025

Any views and opinions expressed are those of the author/presenter, and do not necessarily reflect the views, policy, or position of the Oncology Learning Network, HMP Global, and its employees and affiliates.

Related Content

Quiz

Immune Signatures of Survival in High-Grade Glioma

05/01/2026

Results from a translational analysis of patients with high-grade glioma demonstrated that which of the following immune cell population changes distinguished long-term survivors from short-term survivors?

Results from a translational...

05/01/2026

Oncology

News

HSK42360 Shows Clinical Promise in BRAF V600-Mutant Glioma

04/29/2026

Emily Estrada

Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.

Results from a phase 1 study...

04/29/2026

Oncology

News

Distinct Immune Microenvironment Associated With Long-Term Survival in High-Grade Glioma

03/31/2026

Emily Estrada

Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.

Results from a translational...

03/31/2026

Oncology

Videos

Treating a Patient With BRAF-Altered Recurrent or Refractory Pediatric Low-Grade Glioma

03/30/2026

Matthew Cascio, DO

Matthew Cascio, DO, University of Florida, Gainesville, Florida shares insights into his treatment course for a case of a 6-year-old patient with BRAF V600E-mutated recurrent or refractory low-grade glioma.

Matthew Cascio, DO, University...

03/30/2026

Oncology

Infographic: Oncogenic Drivers of Pediatric Low-Grade Glioma (pLGG)

HMP Global Products

Events